Navigator Medicines, a Scotch Plains, NJ-based biotech company, raised $100M in Series A funding.
The round was led by RA Capital Management and Forbion. In conjunction with the financing, Mr. Joustra and Dr. Andrew Levin, Partner and Managing Director at RA Capital Management, will join the Board of Directors at Navigator.
The company intends to use the funds for the development of NAV-240, as well as a pipeline of OX40L-targeted mono- and bispecific antibodies.
Founded in 2024 as a subsidiary of Sera Medicines, Navigator Medicines is a biotech company leading the advancement of biologics for targeted immune regulation and restoration. it is committed to developing new therapies for patients living with complex, heterogeneous autoimmune diseases.
The company also announced the in-licensing of NAV-240 and an OX40L-targeted portfolio from IMBiologics Corp. NAV-240, formerly known as IMB101, is a clinical-stage bispecific antibody against OX40L and TNFĪ±, two clinically-validated targets that are critical in the pathogenesis of several inflammatory diseases. Dual targeting of both OX40L- and TNFĪ±-driven signaling pathways may improve upon the efficacy of either monotherapy alone as a potential treatment option for complex, heterogenous diseases with unmet medical needs.
Dana McClintock, MD, joined the company as Chief Medical Officer.
FinSMEs
27/08/2024